Of note, there are also studies showing that in murine lung cancer models, p53-deficient tumour cells downregulated antigen presentation by reducing the expression of MHC-I, consequently exhibiting poorer responses to ICB compared to WT p53 expressing tumours [195]. The gene discussed is TP53; the disease is lung carcinoma.